Recently, a ligand for the orphan receptor Mpl was identified as thrombopoietin (TPO), which specifically regulates megakaryocyte differentiation, and it was reported to be expressed mainly in liver and kidney. As it was found that thrombopoietin is also produced in bone marrow stromal cells, we studied further the roles of bone marrow stromal cells on megakaryocytopoiesis and platelet formation. The stromal cells stimulated growth and maturation of bone marrow-derived megakaryocytes in the presence of thrombopoietin, and also supported growth of BaF3 cells expressing exogenous Mpl without thrombopoietin. Thrombopoietin induces drastic
RODUCTION OF blood cells is regulated by the interplay of various cytokines and bone marrow stromal cells.'" Platelets are originally derived from pluripotent hematopoietic stem cells. The stem cells differentiate into committed megakaryocyte progenitors, the megakaryocytes mature by polyploidization and cytoplasmic maturation (megakaryocytopoiesis), and finally the matured megakaryocytes release a number of platelets. Studies on the regulatory mechanisms of this unique differentiation and maturation process have been hampered until very recently because the specific factor regulating megakaryocyte and platelet formation had not been identified.
Souyri et a16 isolated and characterized a murine myeloproliferative leukemia virus, and found that a v-oncogene (v-mpl) encodes for a cellular membrane protein, Mpl, which has considerable homology with the genes encoding cytokine receptor superfamily. Human and mouse c-mpl genes were subsequently cloned and ~haracterized."~ Methia et a l l 0 then found that Mpl is selectively expressed in megakaryocytes, and that antisense oligonucleotides of c-mpl specifically inhibit the formation of megakaryocyte colonies but not that of erythroid or granulocyte-macrophage colonies in vitro. Recently, the cognate ligand for the orphan receptor Mpl was identified as a specific cytokine, thrombopoietin (WO), which regulates the differentiation and maturation of mega-karyocyte~.""~ It was also reported that TPO is mainly expressed in liver and
Little is known about the molecular and cellular mechanisms of WO-induced megakaryocyte maturation and platelet formation. Further, the sensing mechanisms that regulate platelet production in acute thrombocytopenia, as well as steady-state conditions, have not yet been defined. As TPO was found to be produced in bone marrow stromal cells, we studied further the roles of bone marrow stromal cells on megakaryocytopoiesis and platelet formation. TPO induces morphological change of megakaryocytes in total bone marrow cells in vitro, ie, the formation of lengthy beaded cytoplasmic processes (proplatelet formation). However, when we cultured the purified megakaryocytes with the stromal cells with or without "0, we found that most of the megakaryocytes adhered to the stromal cells and remained unchanged, while free megakaryocytes induced proplatelet for-P Blood, Vol 87, No 4 (February 15). 1996: pp 1309-1316 morphological change of megakaryocytes in bone marrow cells in vitro, ie, the formation of lengthy beaded cytoplasmic processes (proplatelet formation). However, when the purified megakaryocytes were cocultured with the stromal cells with or without thrombopoietin, most of the megakaryocytes adhered to the stromal cells and remained unchanged, while free megakaryocytes induced proplatelet formation. These observations indicated that the stromal cells in a hematopoietic microenvironment in bone marrow secrete thrombopoietin and stimulate proliferation and maturation of megakaryocytes, but the interaction of megakaryocytes with the stromal cells may suppress proplatelet formation. mation. Therefore, it is likely that the stromal cells in a hematopoietic microenvironment in bone mmow secrete thrombopoietin and stimulate proliferation and maturation of megakaryocytes (megakaryocytopoiesis), but the interaction of megakaryocytes with the stromal cells may suppress proplatelet formation. We discuss the role of the stromal cells in the hematopoietic microenvironment in bone marrow on megakaryocytopoiesis and proplatelet formation.
MATERIALS AND METHODS

Expression of Mpl.
Human and mouse full-length c-mpl cDNAs were prepared by reverse transcribed-polymerase chain reaction (RT-PCR). For human c-mpl, 5' primers (AGAATICATGGTCAC-CTCCTGC) and P type-specific 3' primer (CTCTAGATCAAG-GCTGCTGCCAATA) were used.' For mouse c-mpl, 5' primer (GGAATTCGAGAAGATGCCCTCTIGG) and 3' primer (TIC-TAGACTGCCTTCAGGGCTG) were used. The obtained cDNAs were sequenced by the M13 dideoxy method and were confirmed to be identical with those already reported?-9 The c-mpl cDNAs (human c-mpl P type, mouse c-mpl and chimera M3 receptor) were inserted downstream of the SRa promoter in the expression vector pME18,I6 which contained the neomycin-resistant gene with the simian virus-40 promoter. The plasmids were transfected into interleukin (IL)-3-dependent mouse proB cells BaF3 by electroporation. Stable transfectants resistant to antibiotic G418 (1 mg/mL) were cloned by limiting dilution, and four of each of the transfectant clones were analyzed.
Isolation and expression of TPO. The mouse TPO cDNAs were isolated from a mouse preadipocyte stromal cell line MC3T3-G2/ PA6 and from primary mouse stromal cells by screening the expression cDNA libraries and by RT-PCR, and the nucleotide sequences of the isolated cDNAs were determined by the M13 dideoxy sequencing method." The full-length cDNAs were inserted in pME18 and expressed in African green monkey kidney COS-7 cells. The conditioned media were prepared by culturing the cells for 3 days without fetal calf serum (FCS). A mock-transfected COS-7 supernatant was prepared as well. All subsequent experiments were done with mouse recombinant TPO derived from COS-7 supernatants.
Cell culture. BaF3 cells and their stable transfectants were maintained in RPM1 1640 medium supplemented with 10% FCS and 500 U/mL of mouse recombinant IL-3 (1.0 X IO6 U/mg; Genzyme, Boston, MA). Mouse stromal PA6 cells or freshly prepared primary mouse stromal cells (3 X 10' cells in 6 cm dish) were cultured in the same medium for 16 hours, and the transfectants expressing cmpl genes were cocultured on the feeder cells in the absence of IL-3 for over 1 week and photographed. ) were separated on 1 S% agarose gels in Tris-borate buffer, and the radicactivity of the cDNA synthesized was counted. The radioactivity was plotted against the number of PCR cycles or against the amounts of the reverse transcribed cDNAs, and the best condition was determined before the quantitative analysis. The PCR cycle used was 25, and 0.5 pg of cDNA was used for each quantitative RT-PCR analysis. The amounts of cDNA synthesized were normalized relative to the amount of PCR product for a housekeeping enzyme HPRT that had been amplified in parallel reactions.
Cell growth assay. Cell proliferation was measured by a colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide Cells
(1 X lo5) in microtiter plates in 100 pL culture medium in the presence or absence of various concentrations of recombinant TPO prepared from COS-7 supernatants were cultured at 37°C for 48 hours. The TPO concentration required for which the BaF3 cells expressing mouse Mpl grew at one half of the maximal growth rate was defined as 1 U/mL. In vitro liquid culture of bone marrow cells and of purified megakaryocytes. Bone marrow cells were freshly prepared from BDFl mice (6to 8-week-old females) by flushing marrow cavities with Iscove's modified Dulbecco's medium (IMDM) through 26-gauge needles. Cells (1 X lo6 cells/mL) were washed and cultured for up to 3 weeks in IMDM containing 10% FCS with or without the 75 rmTlovL KCI, 3 I NI I OVL M@*, 0.5 m m~y L of dATP, dGTP, d m recombinant mouse TPO (50 U/mL) and with or without bone marrow stromal cells, and the morphological changes of the megakaryocytes were monitored. Mouse megakaryocytes were purified from bone marrow by a modified two-step separation technique of Levine et aLz4 Cells were sedimented at unit gravity in 2% to 16% gradient of bovine serum albumin solution, and the isolated megakaryocytes (IO0 cells in 8-well chamber slide of 1 cm') were cultured in IMDM medium containing 5% FCS with or without 50 U/mL of TPO and with or without stromal cells (3 X IO3 cellskhamber). The stable transfectants were then cocultured with mouse stromal PA6 cells, which have preadipocyte characteristics or with mouse primary bone marrow stromal cells freshly prepared. We found that all these transfectants adhere to the stromal cells and grow without IL-3, forming a colony-like structure (Fig 1 A) , although the parental BaF3 cells did not survive more than 2 days. Furthermore, soluble mouse Mpl inhibited cell growth of all these transfectants. These results suggested that bone marrow stromal cells, including the cell line PA6, also secrete the Mpl ligand (TPO), although TPO was reported to be expressed mainly in liver and kidney.".'* Cell proliferation assay confirmed that the conditioned medium prepared from PA6 cells stimulates the growth of BaF3 cells expressing mouse Mpl (Fig lB) , but not of the parental cells, although the level of secreted TPO in the supernatant was too low to support exponential cell growth in suspension.
RESULTS
Bone
Quantitative RT-PCR analysis. We next examined the TPO gene expression in total bone marrow, liver, and kidney by the quantitative RT-PCR analysis, and the relative transcriptional levels were compared. The result shows that TPO transcripts were clearly detected, not only in liver and kidney, but also in total bone marrow cells (Fig 2) . The TPO transcripts were most abundant in liver, and the level of TPO transcripts in bone marrow was about one fifth that of liver. It was also observed that the TPO gene was constitutively expressed in the primary bone marrow stromal cells, as well as the PA6 cells (not shown). These results indicate that TPO is indeed expressed, not only in liver and kidney, but also in bone marrow microenvironment in steady-state conditions.
Stromal TPO support growth of Mpl expressing cells. We then isolated TPO cDNAs from primary stromal cells and from PA6 cells and confirmed that TPOs isolated here are essentially identical with that isolated from hepatocyte,'' except that Se?24 is replaced by Pro. The mouse stromal TPO cDNAs were then expressed in COS-7 cells, and the recombinant TPOs prepared from their conditioned media were used for further analyses. Figure 3 shows that all transfectants expressing human Mpl, mouse Mpl, or M3 (but not cells expressing mouse erythropoietin [EPO] receptor) responded and grew with recombinant mouse full-length TPO in a dose-dependent manner, but that none of these transfectants grew with a mock-transfected COS-7 superna- tant. It was also confirmed that all transfectants can be maintained for a long period in the presence of TPO. The growth rate of the cells expressing human Mpl was slow compared with cells expressing mouse Mpl, probably because the TPO used was of mouse origin. Cells expressing M3 chimera grew rapidly with TPO, indicating that cytoplasmic domains of the chimeric receptor constituted with IL-3 receptor may transmit a growth signal more efficiently in these IL-3dependent cells.
Both TPO and EPO hove strict binding specificit?. to the receptors. The structural analysis has shown that there exists some sequence similarity in TPO and EPO, and in the receptors for TPO and EPO."." It has also been described that high concentration of EPO stimulates megakaryocyto-p~i e s i s .~~~" We, therefore, examined the possibility that EPO and TPO cross-react with each other's receptors. "'I-labeled EPO, however, did not bind to either human Mpl or mouse Mpl (not shown). Further, EPO did not support the growth of the BaF3 transfectants expressing any c-mpl genes. even in the presence of a high concentration of EPO (up to 50 U/ mL) (not shown). Conversely, mouse TPO did not stimulate the growth of BaF3 cells expressing mouse EPO receptor (Fig 3) . Thus, it is concluded that both TPO and EPO have strict binding specificity to the receptor and thus specific biological function.
I n vitro liquid culture qf hone marrow-derived megakanocwes in the presence qf TPO. Freshly prepared mouse bone marrow cells were cultured with recombinant mouse TPO in liquid culture for up to 21 days. and their morphological changes were monitored. In 4 days with TPO, a significant number of large megakaryocytes were produced in the liquid culture, although few megakaryocytes were generated without TPO. Acetylcholinesterase staining confirmed that all these large cells are megakaryocytes, and the Romanoskystained megakaryocytes in this stage clearly showed M3 Human Mpl Nouse TPO] units/ml multilobed nuclei. When these cells were cultured further (5 to 21 days) with TPO, the morphology of the megakaryocytes was dramatically changed (proplatelet formation); they produced lengthy cytoplasmic processes. Without TPO, however, little change in morphology was observed.
When the bone marrow cells were cultured without adherent cells (stromal cells) for over 2 weeks, the number of matured megakaryocytes was much less than that with stromal cells, even in the presence of TPO. On the other hand, when total bone marrow cells were cultured with TPO for over 1 week, and the bone marrow cells in suspension were replated without the adherent stromal cells in new dish, the number of matured megakaryocytes having cytoplasmic processes significantly increased. Figure 4A shows the proplatelet formation under these conditions. These observations suggested that bone marrow stromal cells stimulate megakaryocyte proliferation and maturation (megakaryocytopoiesis), but that the morphological change of the matured megakaryocyte takes place more effectively in the absence of stromal cells. Therefore, the interaction of megakaryocytes with the stromal cells might suppress the final stage of megakaryocyte differentiation, ie, the formation of cytoplasmic processes (proplatelet formation).
Morphological change of purijied megakaryocytes in the presence of TPO and/or stromal cells. To study further the role of the stromal cells on megakaryocyte maturation and proplatelet formation, the megakaryocytes purified from bone marrow were cultured with the stromal cells andor TPO. Figures 4B and C show the morphological changes of the purified megakaryocytes treated with TPO for 3 days in liquid culture. In this system, we can clearly observe a relatively early-stage of morphological changes: a megakaryocyte from which four relatively short cytoplasmic processes are growing ( Fig 4B) and a megakaryocyte containing relatively long and partially beaded cytoplasmic processes ( Fig  4C) . However, we noticed that the purified megakaryocytes (5.1 % of total cells) could induce proplatelet formation even in the absence of TPO within 15 hours, and that the addition of TPO had no effect on proplatelet formation in this period (5.8% of total cells) ( Table 1) . Furthermore, proplatelet formation occurred in the presence or absence of TPO even after 3 days ( Table 2) . Therefore, TPO might function on maturation of megakaryocytes, but might not directly act on proplatelet formation.
When the purified megakaryocytes (100 cells per chamber) were cocultured with PA6 stromal cells (3 X lo3 cells/ I cm2 chamber) with or without 50 U/mL of TPO, about 40% of the megakaryocytes adhered to the stromal cells in 15 hours ( Fig 5A) (Table 1 ). These purified megakaryocytes bound to the stromal cells remained unchanged and no proplatelet formation occurred even in the presence of TPO ( Fig  5A) ( Table 1) . Instead, 3.9% of the megakaryocytes that did not adhere to the stromal cells (about 60% of the total megakaryocytes), could induce proplatelet formation without TPO in 15 hours ( Fig 5B and Table 1 ). In the presence of TPO, 5.7% of free megakaryocytes induced proplatelet formation ( Table 1 ). The percentage of the proplatelets in total megakaryocytes in the absence of stromal cells was about the same range (5.1% to 5.8%) with or without TPO ( Table 1 ). The proplatelet formation of these free megakaryocytes in the presence or absence of stromal cells was only slightly enhanced by TPO addition (Table 1) .
When the purified megakaryocytes were cultured with PA6 cells for 3 days, the number of megakaryocytes adhered to PA6 cells increased to 78% ( Table 2 ). About 7.2% of the free megakaryocytes formed proplatelets after 3 days culture even in the absence of TPO (Fig 5C) (Table 2) , and addition of TPO only slightly enhanced proplatelet formation (8.9% of free megakaryocytes) ( Table 2 ). The megakaryocytes adhered to PA6 cells also formed proplatelets in 3 days culture, but the proplatelet formation was significantly inhibited. Only 1.6% to 2.6% of the adherent cells formed proplatelets with or without TPO ( Table 2) , including the proplatelets that might attach to the stromal cells after proplatelet formation. In the absence of PA6 cells, 12.7% to 15.0% of the megakaryocytes formed proplatelets in the presence or absence of TPO in 3 days culture (Table 2) , which may indicate that the presence of stromal cells inhibits the proplatelet formation of matured megakaryocytes. The possibility that Proplatelet formation with or without stromal cells and/or TPO after 3 days culture. Number indicates the percentage in the total megakaryocytes. Purified megakaryocytes were cocultured with or without PA6 cells and with or without TPO for 3 days, and number of free and adhered megakaryocytes and the number of proplatelets were counted. Numbers indicate the mean values of five independent experiments and the standard deviations. the soluble factor secreted from the PA6 cells inhibited the proplatelet formation was excluded, as the supernatants of PA6 cells did not inhibit proplatelet formation. Thus, it is likely that the free megakaryocytes in the presence of PA6 cells might occasionally interact with the stromal cells during 3 days culture, and the interaction of megakaryocytes and the stromal cells inhibited the proplatelet formation. Taken together, these results suggested that TPO stimulates megakaryocyte growth and maturation in vitro liquid culture, and that the interaction of the stromal cells with the megakaryocytes may suppress the formation of cytoplasmic processes from which the platelets are released.
DISCUSSION
Hematopoiesis takes place principally in the bone marrow in adult mammals. The steady-state production of blood cells depends on the interaction between hematopoietic stem cells (and progenitor cells of various lineages) and the various components of the microenvironment present in the medullary cavity. The hematopoietic microenvironment is composed of stromal cells such as fibroblasts, macrophages, endothelial cells and adipocytes, and accessory cells such as T lymphocytes and monocytes, which are surrounded by various extracellular matrixes and cytokines. The regulatory mechanism of megakaryocyte and platelet production has not been identified, but it is likely that the stromal cells in the bone marrow microenvironment of the medullary cavity stimulate megakaryocytopoiesis by interacting with hematopoietic stem cells and/or megakaryocyte progenitor cells and by secreting a key regulatory factor, TPO, with the aid of the liver and kidney TPO. On the other hand, the stromal cells might suppress the production of platelets, by interacting with the matured megakaryocytes in bone marrow and by inhibiting the formation of cytoplasmic processes, from which a number of platelets are released. Therefore, in vivo platelet formation may be triggered by the release of the matured megakaryocytes from the stromal cells in the bone marrow microenvironment. It should be clarified how and why the interaction of the stromal cells with the megakaryocytes blocks the proplatelet formation. The fact that the bone marrow stromal cells function positively on megakaryocytopoiesis and negatively on proplatelet formation is consistent with all the previously known concepts, but further detailed analyses are required to clarify the molecular and cellular regulatory mechanism of megakaryocytopoiesis and platelet formation by bone marrow stromal cells.
Very recently, Choi et alZ8 demonstrated that human CD34' progenitor cells obtained from peripheral blood differentiated into platelets in vitro, and their results are consistent with our data obtained with mouse bone marrow and with purified mouse megakaryocytes. The development of platelets from the hematopoietic stem cells is a sequential process of proliferation of the committed megakaryocyte progenitors, nuclear polyploidization and cytoplasmic maturation of the megakaryocytes, and, finally, proplatelet formation followed by platelet release. It is possible to observe the dramatic morphological change of megakaryocytes in liquid culture in vitro in the presence or absence of TPO and/or stromal cells. This in vitro system was found to be a powerful means for the study of the molecular and cellular mechanism of megakaryocyte maturation and platelet release.
